Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen (Q33383340)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen |
scientific article |
Statements
1 reference
Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen (English)
1 reference
James R Berenson
1 reference
Ori Yellin
1 reference
Donald Woytowitz
1 reference
Marshall S Flam
1 reference
Alan Cartmell
1 reference
Ravi Patel
1 reference
Herb Duvivier
1 reference
Youram Nassir
1 reference
Benjamin Eades
1 reference
Christina Dilauro Abaya
1 reference
Jacqueline Hilger
1 reference
Regina A Swift
1 reference
17 February 2009
1 reference
1 reference
82
1 reference
433-439
1 reference
Identifiers
1 reference
1 reference